文献速递消化系统肿瘤

ENT1与MATE1/OCT2基因多态性预测TAS-102治疗难治性转移性结直肠癌的疗效与毒性

Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer.
PubMed 文献 · Eur J Cancer · 2017-10-06

本研究在训练队列(n=52)和验证队列(n=129)的TAS-102治疗mCRC患者及对照队列(n=52)的瑞戈非尼治疗患者中,分析TK1、ENT1、CNT1、MATE1、MATE2和OCT2的SNP。训练队列中ENT1 rs760370任一G等位基因患者较A/A基因型PFS显著延长(3.5 vs 2.1个月,HR 0.44,P=0.004)且OS显著延长(8.7 vs 5.3个月,HR 0.27,P=0.003),并在验证队列中得到验证。ENT1、MATE1和OCT2 SNP组合可显著分层PFS和OS风险。

要点

  • ENT1 rs760370 G等位基因与TAS-102治疗mCRC患者更长的PFS和OS相关。
  • ENT1、MATE1和OCT2 SNP组合可显著分层TAS-102治疗患者的PFS和OS风险。
  • 对照队列(瑞戈非尼)中未观察到显著差异。

核心结论

  • ENT1、MATE1和OCT2 SNP组合可能作为TAS-102治疗mCRC患者的预测和预后标志物。

研究设计与样本

  • 研究纳入三个队列:训练队列(n=52)和验证队列(n=129)均接受TAS-102治疗,对照队列(n=52)接受瑞戈非尼治疗。
  • 采用聚合酶链反应直接DNA测序分析TK1、ENT1、CNT1、MATE1、MATE2和OCT2的SNP。

主要发现

  • 训练队列中,ENT1 rs760370任一G等位基因患者较A/A基因型PFS显著延长(3.5 vs 2.1个月,HR 0.44,P=0.004)且OS显著延长(8.7 vs 5.3个月,HR 0.27,P=0.003)。
  • 验证队列中验证了上述发现(PFS P=0.021,OS P=0.009)。
  • ENT1 rs760370、MATE1 rs2289669和OCT2 rs316019 SNP组合在两个队列中均显著分层PFS和OS风险(训练队列PFS和OS均P<0.001;验证队列PFS P=0.053,OS P=0.025)。
  • 对照组中未观察到显著差异。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Trifluridine (FTD) is an active cytotoxic component of the metastatic colorectal cancer (mCRC) drug TAS-102, and thymidine phosphorylase inhibitor (TPI) inhibits the rapid degradation of FTD. We tested whether single nucleotide polymorphisms (SNPs) in genes involved in FTD metabolism and TPI excretion could predict outcome in patients with mCRC treated with TAS-102. PATIENTS AND METHODS: We investigated three different cohorts: a training cohort (n = 52) and a testing cohort (n = 129) both receiving TAS-102 and a control cohort (n = 52) receiving regorafenib. SNPs of TK1, ENT1, CNT1, MATE1, MATE2 and OCT2 were analysed by polymerase chain reaction-based direct DNA sequencing. RESULTS: In the training cohort, patients with any ENT1 rs760370 G allele had a significantly longer progression-free survival (PFS; 3.5 versus 2.1 months, respectively, hazard ratio [HR] 0.44, P = 0.004) and overall survival (OS; 8.7 versus 5.3 months, respectively, HR 0.27, P = 0.003) than the A/A genotype. These findings were validated in the testing cohort (P = 0.021 and 0.009 for PFS and OS, respectively). In addition, the combination of ENT1 rs760370, MATE1 rs2289669 and OCT2 rs316019 SNPs significantly stratified patients with the risk of PFS and OS in both cohorts (P < 0.001 for PFS and OS in the training cohort; P = 0.053 and 0.025 for PFS and OS, respectively, in the testing cohort). No significant differences were observed in the control group. CONCLUSIONS: The combination of ENT1, MATE1 and OCT2 SNPs may serve as a predictive and prognostic marker in mCRC patients treated with TAS-102.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Suenaga M, Schirripa M, Cao S, et al. Potential role of polymorphisms in the transporter genes ENT1 and MATE1/OCT2 in predicting TAS-102 efficacy and toxicity in patients with refractory metastatic colorectal cancer. Eur J Cancer. 2017. PMID: 28992563. doi:10.1016/j.ejca.2017.08.033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。